What's happening at HerelleX?
Milestones, scientific progress and company updates.
4 notes
CompanyHerelleX closes its first investment round
The company secures the funding to scale FluoTB and prepare its regional launch.
PartnershipsNew agreement with laboratories across the region
Four reference laboratories join the validation of FluoTB under routine conditions.
ScienceFluoTB detects resistant tuberculosis in under an hour
An internal trial on 240 clinical samples confirmed the system identifies rifampicin-resistant strains in an average of 52 minutes.
ScienceWe open our phage production laboratory in Montevideo
An in-house facility to produce the reporter phages FluoTB relies on, ending our dependence on imported batches with six-week lead times.
Get involved
Bring FluoTB to where it's needed.
The potential market is ~200,000 tests a year in Argentina and over 30 million a year across high-incidence countries — a global TB-diagnostics market projected to grow from USD 2.28B in 2024 to USD 3.18B by 2030. If accessible diagnosis is your mission too, let's talk.
Simplified view
One sample. One test, adjusted to routine lab workflows.
A respiratory sample is processed with standard lab methods, incubated with our reagents, then fixed for safe fluorescence reading — even up to 10 days later.
01.
Decontamination
Competing flora is cleared.
02.
Infect and express
Sample meets phage reagents.
03.
Fixation
Fixed — safe to handle and store.